Taken together, these findings suggest that immunotherapy using an FAP-expressing vaccine induces immunity to both TAAs and FAP and stimulates the formation tumor-specific CTLs, predominantly CD8+ cells, which are directed toward antigens associated with the patient’s cancer. The gene discussed is FAP; the disease is neoplasm.